{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:05:40Z","timestamp":1794409540043,"version":"4.9.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:00:00Z","timestamp":1744502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:00:00Z","timestamp":1744502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016646","name":"HCA Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40265-025-02177-x","type":"journal-article","created":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T16:16:52Z","timestamp":1744561012000},"page":"813-825","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2751-3783","authenticated-orcid":false,"given":"Feras","family":"Al-Moussally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saud","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Katukuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Kinaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishak A.","family":"Mansi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,13]]},"reference":[{"key":"2177_CR1","unstructured":"Alcohol Fact Sheets. World Health Organization; 2024. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/alcohol. (last accessed Aug 8, 2024)."},{"issue":"10129","key":"2177_CR2","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(18)30134-X","volume":"391","author":"AM Wood","year":"2018","unstructured":"Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet. 2018;391(10129):1513\u201323.","journal-title":"Lancet"},{"key":"2177_CR3","unstructured":"Alcohol Abuse Statistics. National Center for Drug Abuse Statistics. Available at: https:\/\/drugabusestatistics.org\/alcohol-abuse-statistics\/ (last accessed Aug 8, 2024)."},{"issue":"9","key":"2177_CR4","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/j.mayocp.2020.01.030","volume":"95","author":"J Fairbanks","year":"2020","unstructured":"Fairbanks J, Umbreit A, Kolla BP, Karpyak VM, Schneekloth TD, Loukianova LL, et al. Evidence-based pharmacotherapies for alcohol use disorder: clinical pearls. Mayo Clin Proc. 2020;95(9):1964\u201377.","journal-title":"Mayo Clin Proc"},{"issue":"17","key":"2177_CR5","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.2023.19761","volume":"330","author":"M McPheeters","year":"2023","unstructured":"McPheeters M, O\u2019Connor EA, Riley S, Kennedy SM, Voisin C, Kuznacic K, et al. Pharmacotherapy for alcohol use disorder. JAMA. 2023;330(17):1653.","journal-title":"JAMA"},{"key":"2177_CR6","unstructured":"Latif W, Lambrinos KJ, Rodriguez R. Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs). StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2024, StatPearls Publishing LLC.; 2024."},{"issue":"12","key":"2177_CR7","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.120.045888","volume":"142","author":"MS Khan","year":"2020","unstructured":"Khan MS, Fonarow GC, McGuire DK, Hernandez AF, Vaduganathan M, Rosenstock J, et al. Glucagon-like peptide 1 receptor agonists and heart failure. Circulation. 2020;142(12):1205\u201318.","journal-title":"Circulation"},{"issue":"4","key":"2177_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061965","volume":"8","author":"RH Shirazi","year":"2013","unstructured":"Shirazi RH, Dickson SL, Skibicka KP. Gut peptide GLP-1 and its analogue, exendin-4, decrease alcohol intake and reward. PLoS\u00a0One. 2013;8(4): e61965.","journal-title":"PLoS\u00a0One"},{"issue":"2","key":"2177_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/adb.12295","volume":"21","author":"D Vall\u00f6f","year":"2016","unstructured":"Vall\u00f6f D, Maccioni P, Colombo G, Mandrapa M, J\u00f6rnulf JW, Egecioglu E, et al. The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict Biol. 2016;21(2):422\u201337.","journal-title":"Addict Biol"},{"issue":"6","key":"2177_CR10","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00213-023-06376-w","volume":"240","author":"RJ Herman","year":"2023","unstructured":"Herman RJ, Hayes MR, Audrain-Mcgovern J, Ashare RL, Schmidt HD. Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats. Psychopharmacology. 2023;240(6):1373\u201386.","journal-title":"Psychopharmacology"},{"key":"2177_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.brainresbull.2022.08.023","volume":"189","author":"LA Urbanik","year":"2022","unstructured":"Urbanik LA, Acharya NK, Grigson PS. Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats. Brain Res Bull. 2022;189:155\u201362.","journal-title":"Brain Res Bull"},{"key":"2177_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/adb.13117","author":"JE Douton","year":"2022","unstructured":"Douton JE, Horvath N, Mills-Huffnagle S, Nyland JE, Hajnal A, Grigson PS. Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats. Addiction Biol. 2022. https:\/\/doi.org\/10.1111\/adb.13117.","journal-title":"Addiction Biol"},{"issue":"5","key":"2177_CR13","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/FBP.0000000000000685","volume":"33","author":"JE Douton","year":"2022","unstructured":"Douton JE, Acharya NK, Stoltzfus B, Sun D, Grigson PS, Nyland JE. Acute glucagon-like peptide-1 receptor agonist liraglutide prevents cue-, stress-, and drug-induced heroin-seeking in rats. Behav Pharmacol. 2022;33(5):364\u201378.","journal-title":"Behav Pharmacol"},{"issue":"4","key":"2177_CR14","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1152\/physrev.00014.2018","volume":"99","author":"ND Volkow","year":"2019","unstructured":"Volkow ND, Michaelides M, Baler R. The neuroscience of drug reward and addiction. Physiol Rev. 2019;99(4):2115\u201340.","journal-title":"Physiol Rev"},{"issue":"2","key":"2177_CR15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00213-018-5089-z","volume":"236","author":"M Thomsen","year":"2019","unstructured":"Thomsen M, Holst JJ, Molander A, Linnet K, Ptito M, Fink-Jensen A. Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys. Psychopharmacology. 2019;236(2):603\u201311.","journal-title":"Psychopharmacology"},{"issue":"8","key":"2177_CR16","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.psyneuen.2012.11.009","volume":"38","author":"E Egecioglu","year":"2013","unstructured":"Egecioglu E, Steensland P, Fredriksson I, Feltmann K, Engel JA, Jerlhag E. The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology. 2013;38(8):1259\u201370.","journal-title":"Psychoneuroendocrinology"},{"key":"2177_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.599646","author":"VN Marty","year":"2020","unstructured":"Marty VN, Farokhnia M, Munier JJ, Mulpuri Y, Leggio L, Spigelman I. Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male wistar rats. Front Neurosci. 2020. https:\/\/doi.org\/10.3389\/fnins.2020.599646.","journal-title":"Front Neurosci"},{"issue":"4","key":"2177_CR18","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s11064-023-04093-6","volume":"49","author":"W Liu","year":"2024","unstructured":"Liu W, Wang Z, Wang W, Wang Z, Xing Y, H\u00f6lscher C. Liraglutide Reduces Alcohol Consumption, Anxiety, Memory Impairment, and Synapse Loss in Alcohol Dependent Mice. Neurochem Res. 2024;49(4):1061\u201375.","journal-title":"Neurochem Res"},{"key":"2177_CR19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.neuropharm.2019.02.020","volume":"149","author":"D Vall\u00f6f","year":"2019","unstructured":"Vall\u00f6f D, Vestlund J, Jerlhag E. Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents. Neuropharmacology. 2019;149:124\u201332.","journal-title":"Neuropharmacology"},{"key":"2177_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104642","volume":"93","author":"C Aran\u00e4s","year":"2023","unstructured":"Aran\u00e4s C, Edvardsson CE, Shevchouk OT, Zhang Q, Witley S, Blid Sk\u00f6ldheden S, et al. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine. 2023;93:104642.","journal-title":"EBioMedicine"},{"key":"2177_CR21","doi-asserted-by":"crossref","unstructured":"Zorrilla EP, Koob GF. Impulsivity derived from the dark side: neurocircuits that contribute to negative urgency. Front Behav Neurosci. 2019;13.","DOI":"10.3389\/fnbeh.2019.00136"},{"key":"2177_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00655","author":"SP Neupane","year":"2016","unstructured":"Neupane SP. Neuroimmune interface in the comorbidity between alcohol use disorder and major depression. Front Immunol. 2016. https:\/\/doi.org\/10.3389\/fimmu.2016.00655.","journal-title":"Front Immunol"},{"key":"2177_CR23","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.neuropharm.2014.10.014","volume":"89","author":"M Pascual","year":"2015","unstructured":"Pascual M, Bali\u00f1o P, Arag\u00f3n CMG, Guerri C. Cytokines and chemokines as biomarkers of ethanol-induced neuroinflammation and anxiety-related behavior: role of TLR4 and TLR2. Neuropharmacology. 2015;89:352\u20139.","journal-title":"Neuropharmacology"},{"issue":"2\u20133","key":"2177_CR24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/BF02245161","volume":"107","author":"H De Wit","year":"1992","unstructured":"De Wit H, Bodker B, Ambre J. Rate of increase of plasma drug level influences subjective response in humans. Psychopharmacology. 1992;107(2\u20133):352\u20138.","journal-title":"Psychopharmacology"},{"issue":"3","key":"2177_CR25","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1053\/gast.1997.v112.pm9041238","volume":"112","author":"S Yin","year":"1997","unstructured":"Yin S, Liao C, Wu C, Li T, Chen L, Lai C, et al. Human stomach alcohol and aldehyde dehydrogenases: comparison of expression pattern and activities in alimentary tract. Gastroenterology. 1997;112(3):766\u201375.","journal-title":"Gastroenterology"},{"issue":"5","key":"2177_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/bcpt.13776","volume":"131","author":"IK Wium-Andersen","year":"2022","unstructured":"Wium-Andersen IK, Wium-Andersen MK, Fink-Jensen A, Rungby J, Jorgensen MB, Osler M. Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study. Basic Clin Pharmacol Toxicol. 2022;131(5):372\u20139.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2177_CR27","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159863","author":"MK Klausen","year":"2022","unstructured":"Klausen MK, Jensen ME, Moller M, Le Dous N, Jensen AO, Zeeman VA, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022. https:\/\/doi.org\/10.1172\/jci.insight.159863.","journal-title":"JCI Insight."},{"key":"2177_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330962","author":"A Wester","year":"2024","unstructured":"Wester A, Shang Y, Toresson Grip E, Matthews AA, Hagstr\u00f6m H. Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes. Gut. 2024. https:\/\/doi.org\/10.1136\/gutjnl-2023-330962.","journal-title":"Gut"},{"key":"2177_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03228-4","author":"F-S Yen","year":"2024","unstructured":"Yen F-S, Hou M-C, Wei JC-C, Shih Y-H, Hwu C-M, Hsu C-C. Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes. BMC Med. 2024. https:\/\/doi.org\/10.1186\/s12916-023-03228-4.","journal-title":"BMC Med"},{"key":"2177_CR30","doi-asserted-by":"crossref","unstructured":"<i>Standards of Medical Care in Diabetes\u20142021<\/i> Abridged for Primary Care Providers. Clinical Diabetes. 2021;39(1):14-43.","DOI":"10.2337\/cd21-as01"},{"issue":"4","key":"2177_CR31","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.beem.2007.07.005","volume":"21","author":"B Ahren","year":"2007","unstructured":"Ahren B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab. 2007;21(4):517\u201333.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"2177_CR32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/14728214.2016.1257608","volume":"21","author":"A Cahn","year":"2016","unstructured":"Cahn A, Cernea S, Raz I. An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opin Emerg Drugs. 2016;21(4):409\u201319.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"24","key":"2177_CR33","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","volume":"146","author":"N Marx","year":"2022","unstructured":"Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022;146(24):1882\u201394.","journal-title":"Circulation"},{"key":"2177_CR34","unstructured":"VA Informatics and Computing Infrastructure (VINCI), VA HSR RES 13-457, U.S. Department of Veterans Affairs. (2008). Retrieved [date], from https:\/\/vincicentral.vinci.med.va.gov."},{"issue":"3","key":"2177_CR35","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1530-0277.2012.01937.x","volume":"37","author":"KA McGinnis","year":"2013","unstructured":"McGinnis KA, Justice AC, Kraemer KL, Saitz R, Bryant KJ, Fiellin DA. Comparing alcohol screening measures among HIV-infected and -uninfected men. Alcohol Clin Exp Res. 2013;37(3):435\u201342.","journal-title":"Alcohol Clin Exp Res"},{"key":"2177_CR36","unstructured":"Clinical Classifications Software (CCS) for ICD-9-CM. U.S. Agency for Healthcare Research and Quality. Available atL http:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/ccs\/ccs.jsp. (last accessed march 16, 2024)"},{"key":"2177_CR37","unstructured":"Clinical Classifications Software Refined (CCSR). Healthcare Cost and Utilization Project (HCUP). April 2024. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov\/toolssoftware\/ccsr\/ccs_refined.jsp. (last accessed Aug 8, 2024)"},{"issue":"1","key":"2177_CR38","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/hep.31726","volume":"74","author":"H Hagstr\u00f6m","year":"2021","unstructured":"Hagstr\u00f6m H, Adams LA, Allen AM, Byrne CD, Chang Y, Gr\u00f8nbaek H, et al. Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement. Hepatology. 2021;74(1):474\u201382.","journal-title":"Hepatology"},{"issue":"4","key":"2177_CR39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund JL, Richardson DB, Sturmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2(4):221\u20138.","journal-title":"Curr Epidemiol Rep."},{"issue":"3","key":"2177_CR40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","volume":"21","author":"M Lipsitch","year":"2010","unstructured":"Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21(3):383\u20138.","journal-title":"Epidemiology"},{"issue":"9","key":"2177_CR41","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1007\/s10620-018-5123-3","volume":"63","author":"YA Patel","year":"2018","unstructured":"Patel YA, Gifford EJ, Glass LM, Turner MJ, Han B, Moylan CA, et al. Identifying nonalcoholic fatty liver disease advanced fibrosis in the veterans health administration. Dig Dis Sci. 2018;63(9):2259\u201366.","journal-title":"Dig Dis Sci"},{"issue":"12","key":"2177_CR42","doi-asserted-by":"publisher","first-page":"CR35","DOI":"10.12659\/MSM.883601","volume":"18","author":"H Cicho\u017c-Lach","year":"2012","unstructured":"Cicho\u017c-Lach H, Celi\u0144ski K, Prozorow-Kr\u00f3l B, Swatek J, S\u0142omka M, Lach T. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. Med Sci Monit. 2012;18(12):CR35\u201340.","journal-title":"Med Sci Monit"},{"issue":"7","key":"2177_CR43","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"JH Lee","year":"2010","unstructured":"Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503\u20138.","journal-title":"Dig Liver Dis"},{"issue":"7","key":"2177_CR44","first-page":"477","volume":"101","author":"FC Kruger","year":"2011","unstructured":"Kruger FC, Daniels CR, Kidd M, Swart G, Brundyn K, van Rensburg C, et al. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD\/NASH. S Afr Med J. 2011;101(7):477\u201380.","journal-title":"S Afr Med J"},{"issue":"8","key":"2177_CR45","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1093\/gerona\/gly232","volume":"74","author":"AR Orkaby","year":"2019","unstructured":"Orkaby AR, Nussbaum L, Ho YL, Gagnon D, Quach L, Ward R, et al. The burden of frailty among U.S. veterans and its association with mortality, 2002\u20132012. J Gerontol A Biol Sci Med Sci. 2019;74(8):1257\u201364.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"4","key":"2177_CR46","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/1475-6773.00165","volume":"38","author":"S Schneeweiss","year":"2003","unstructured":"Schneeweiss S, Wang PS, Avorn J, Glynn RJ. Improved comorbidity adjustment for predicting mortality in medicare populations. Health Serv Res. 2003;38(4):1103\u201320.","journal-title":"Health Serv Res"},{"issue":"6","key":"2177_CR47","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"key":"2177_CR48","unstructured":"Elixhauser A, Steiner C, Palmer L. Clinical Classifications Software (CCS) for ICD-9-CM. Databases and Related Tools from the Healthcare Cost and Utilization Project (HCUP) U.S. Agency for Healthcare Research and Quality; 2012:Appendix A"},{"issue":"6","key":"2177_CR49","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"2177_CR50","first-page":"358","volume":"2","author":"S Becker","year":"2002","unstructured":"Becker S, Ichino A. Estimation of average treatment effects based on propensity scores. Stand Genomic Sci. 2002;2(4):358\u201377.","journal-title":"Stand Genomic Sci"},{"key":"2177_CR51","unstructured":"Leuven E, Sianesi B. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. available at: http:\/\/ideas.repec.org\/c\/boc\/bocode\/s432001.html. version 4.0.5 ed; 2003."},{"issue":"1\u20133","key":"2177_CR52","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.drugalcdep.2008.07.018","volume":"99","author":"TL Mark","year":"2009","unstructured":"Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009;99(1\u20133):345\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"2177_CR53","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.170419","author":"L Probst","year":"2023","unstructured":"Probst L, Monnerat S, Vogt DR, Lengsfeld S, Burkard T, Meienberg A, et al. Effects of dulaglutide on alcohol consumption during smoking cessation. JCI Insight. 2023. https:\/\/doi.org\/10.1172\/jci.insight.170419.","journal-title":"JCI Insight."},{"issue":"2","key":"2177_CR54","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/add.16679","volume":"120","author":"F Qeadan","year":"2025","unstructured":"Qeadan F, McCunn A, Tingey B. The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: a real-world data analysis. Addiction. 2025;120(2):236\u201350.","journal-title":"Addiction"},{"issue":"4","key":"2177_CR55","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/S0016-5085(97)70142-2","volume":"112","author":"A Luca","year":"1997","unstructured":"Luca A, Garc\u00eda-Pag\u00e1n JC, Bosch J, Feu F, Caballer\u00eda J, Groszmann RJ, et al. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterology. 1997;112(4):1284\u20139.","journal-title":"Gastroenterology"},{"issue":"5","key":"2177_CR56","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1360-0443.2009.02521.x","volume":"104","author":"C Verrill","year":"2009","unstructured":"Verrill C, Markham H, Templeton A, Carr NJ, Sheron N. Alcohol-related cirrhosis\u2013early abstinence is a key factor in prognosis, even in the most severe cases. Addiction. 2009;104(5):768\u201374.","journal-title":"Addiction"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02177-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02177-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02177-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T15:02:06Z","timestamp":1748012526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02177-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,13]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2177"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02177-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,13]]},"assertion":[{"value":"17 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Resources of the Orlando VA Medical Center were used to conduct the study. This work was supported, in part or in whole, by HCA Healthcare and\/or an HCA Healthcare affiliated entity.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of Sponsor"}},{"value":"The authors declare that they do not have a financial conflict of interest related to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest\/Disclosure"}},{"value":"The views expressed herein are those of the authors and do not reflect the official policy or position of the Veterans Health Administration, or the US Government or any of its affiliated entities. Some of the authors are employees of the US government. This work was prepared as part of their official duties and, as such, there is no copyright to be transferred. The views expressed in this publication represent those of the author(s) and do not necessarily represent the official views of HCA Healthcare or any of its affiliated entities.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"Data are stored in the VA Informatics and Computing Infrastructure (VINCI), the operational platform for health services research at the Veterans Healthcare Administration (VHA). VINCI acts as data steward for VHA Data Systems. Data in VINCI cannot be copied, transferred, or printed. Access to data by other researchers is possible following VINCI protocols, as described in the VINCI Central website: .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"The Orlando VA institutional review board approved the study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The Orlando VA institutional review board waived the need for participants\u2019 informed consent since only preexisting deidentified data were used.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"FA: study concept and design, interpretation of data, and drafting of the manuscript. SK: study concept and design, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. VK: study concept and design, interpretation of data, and critical revision of the manuscript for important intellectual content. MK: study concept and design, interpretation of data, critical revision of the manuscript for important intellectual content, and study supervision. IM: study concept and design, acquisition of data along with statistical analysis, interpretation of data, critical revision of the manuscript for important intellectual content, and study supervision.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable.","order":11,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}